Misplaced Pages

Mozavaptan: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 10:37, 12 October 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (repor...← Previous edit Revision as of 22:08, 14 October 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or bugs)Next edit →
Line 1: Line 1:
{{Drugbox {{Drugbox
| verifiedrevid = 455184213 | verifiedrevid = 455185272
| IUPAC_name = ''N''--2-methylbenzamide | IUPAC_name = ''N''--2-methylbenzamide
| image = Mozavaptan structure.svg | image = Mozavaptan structure.svg

Revision as of 22:08, 14 October 2011

Pharmaceutical compound
Mozavaptan
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • N--2-methylbenzamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H29N3O2
Molar mass427.53 g/mol g·mol
3D model (JSmol)
SMILES
  • CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
InChI
  • InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
  • Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N
  (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References

Diuretics (C03)
Sulfonamides
(and etacrynic acid)
CA inhibitors (at PT)
Loop (Na-K-Cl at AL)
Thiazides (Na-Cl at DCT,
Calcium-sparing)
Thiazide-likes (primarily DCT)
Potassium-sparing (at CD)
ESC blockers
Aldosterone antagonists
Osmotic diuretics (PT, DL)
Vasopressin receptor inhibitors
(DCT and CD)
Other
Combination products

Template:Neuropeptide agonists and antagonists


Stub icon

This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Mozavaptan: Difference between revisions Add topic